Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

• Biological: 13 valent Pneumococcal Conjugate Vaccine
  
  0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
• Biological: 23vPS
  
  0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1

• Experimental: 1
  
  Receives 13vPnC at year 0 and 13vPnC at year 1
  Intervention: Biological: 13 valent Pneumococcal Conjugate Vaccine
• Active Comparator: 2
  
  Receives 23vPS at year 0 and 13vPnC at year 1
  Intervention: Biological: 23vPS

Inclusion Criteria:

• Male or Female aged 70 years or older.
• Documented vaccination with 1 dose of 23vPS at least 5 years previous.
• Healthy.

Exclusion Criteria:

• Receipt of more than one dose of 23vPS prior to enrollment.
• History of severe adverse reaction to a vaccine.
• Immunodeficiency.